Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
Circulating microparticles (cMPs) are emerging as biomarkers of cardiovascular disease (CVD). We analyzed cMPs in 200 STEMI patients in a median of 28 h after the onset of symptoms. Monocyte-derived cMPs in the acute phase of STEMI are related to the long-term prognosis for CV death. These findings may be a useful tool to improve prognosis at the long-term in STEMI patients.